Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 12/20 | 0.73 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.70 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.70 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.70 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | QPCT | Q16769 | 1/20 | 0.67 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.67 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.67 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024261 | 0.90 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.88 | CYP11B1 (0.81) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL24733003 | 0.86 | CYP11B1 (0.71) | CYP11B1CYP11B2CYP19A1TBXAS1CYP1A2 | |
| SCHEMBL77025 | 0.85 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL6057476 | 0.84 | CYP11B1 (0.75) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2529997 | 0.84 | CYP11B1 (0.86) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL30946847 | 0.83 | CYP11B1 (0.96) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL570342 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2729830 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL4700517 | 0.81 | CYP11B1 (0.69) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110799500-B | Degradable imidazolium oligomers and polymers for antimicrobial applications | 新加坡科技研究局 | 2023-10-03 | — | — | CN | disclosed |
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| EP-3621955-B1 | DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS | AGENCY SCIENCE TECH & RES (SG) | 2021-07-14 | — | — | EP | disclosed |
| EP-3621955-B1 | DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS | AGENCY SCIENCE TECH & RES (SG) | 2021-07-14 | — | — | EP | disclosed |
| US-10927100-B2 | Degradable imidazolium oligomer and polymer for antimicrobial applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-23 | — | — | US | disclosed |
| US-10927100-B2 | Degradable imidazolium oligomer and polymer for antimicrobial applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-23 | — | — | US | disclosed |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-20200181122-A1 | Degradable Imidazolium Oligomer and Polymer for Antimicrobial Applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-11 | — | — | US | disclosed |
| US-20200181122-A1 | Degradable Imidazolium Oligomer and Polymer for Antimicrobial Applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-11 | — | — | US | disclosed |
| EP-3621955-A1 | DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS | Agency for Science, Technology and Research (SG) | 2020-03-18 | — | — | EP | disclosed |
| WO-2019004940-A1 | DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019004940-A1 | DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-03 | — | — | WO | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| EP-0230035-B1 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID CO (US) | 1994-10-12 | — | — | EP | disclosed |
| US-4728663-A | HYPOTENSIVE, ANTIARRHYTHMIA | AMERICAN CYANAMID COMPANY (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0230035-A2 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | RORA, RORC, RORB | CYP11B1 138/4885CYP11B2 161/4885CYP19A1 233/4885 |
| US-10927100-B2 | Degradable imidazolium oligomer and polymer for antimicrobial applications | NOD2, CFTR, PUF60 | CYP11B1 3790/4885CYP11B2 3749/4885CYP19A1 4646/4885 |
| US-20200181122-A1 | Degradable Imidazolium Oligomer and Polymer for Antimicrobial Applications | NOD2, CFTR, PUF60 | CYP11B1 3790/4885CYP11B2 3749/4885CYP19A1 4646/4885 |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | CYP11B1 110/4885CYP11B2 118/4885CYP19A1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.